152 related articles for article (PubMed ID: 22623146)
21. In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.
Villemagne VL; Okamura N; Pejoska S; Drago J; Mulligan RS; Chételat G; Ackermann U; O'Keefe G; Jones G; Gong S; Tochon-Danguy H; Kung HF; Masters CL; Skovronsky DM; Rowe CC
Arch Neurol; 2011 Jul; 68(7):905-12. PubMed ID: 21747030
[TBL] [Abstract][Full Text] [Related]
22. Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging ([(18)F]AV-133).
Liu Y; Yue F; Tang R; Tao G; Pan X; Zhu L; Kung HF; Chan P
Neurosci Bull; 2014 Jun; 30(3):409-16. PubMed ID: 24061965
[TBL] [Abstract][Full Text] [Related]
23. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
24. Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.
Villemagne VL; Okamura N; Pejoska S; Drago J; Mulligan RS; Chételat G; O'Keefe G; Jones G; Kung HF; Pontecorvo M; Masters CL; Skovronsky DM; Rowe CC
Neurodegener Dis; 2012; 10(1-4):161-5. PubMed ID: 22261520
[TBL] [Abstract][Full Text] [Related]
25. Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET.
Lin KJ; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Hsiao IT
PLoS One; 2013; 8(9):e75952. PubMed ID: 24098749
[TBL] [Abstract][Full Text] [Related]
26. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent.
Lin KJ; Weng YH; Wey SP; Hsiao IT; Lu CS; Skovronsky D; Chang HP; Kung MP; Yen TC
J Nucl Med; 2010 Sep; 51(9):1480-5. PubMed ID: 20720042
[TBL] [Abstract][Full Text] [Related]
27. Chronic manganism: A long-term follow-up study with a new dopamine terminal biomarker of 18F-FP-(+)-DTBZ (18F-AV-133) brain PET scan.
Huang CY; Liu CH; Tsao E; Hsieh CJ; Weng YH; Hsiao IT; Yen TC; Lin KJ; Huang CC
J Neurol Sci; 2015; 353(1-2):102-6. PubMed ID: 25936253
[TBL] [Abstract][Full Text] [Related]
28. An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2.
Zhu L; Liu Y; Plössl K; Lieberman B; Liu J; Kung HF
Nucl Med Biol; 2010 Feb; 37(2):133-41. PubMed ID: 20152712
[TBL] [Abstract][Full Text] [Related]
29. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus.
Kung MP; Hou C; Lieberman BP; Oya S; Ponde DE; Blankemeyer E; Skovronsky D; Kilbourn MR; Kung HF
J Nucl Med; 2008 Jul; 49(7):1171-6. PubMed ID: 18552132
[TBL] [Abstract][Full Text] [Related]
30. Effects of anesthetics on vesicular monoamine transporter type 2 binding to ¹⁸F-FP-(+)-DTBZ: a biodistribution study in rat brain.
Chen Z; Tang J; Liu C; Li X; Huang H; Xu X; Yu H
Nucl Med Biol; 2016 Jan; 43(1):124-129. PubMed ID: 26526872
[TBL] [Abstract][Full Text] [Related]
31. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.
Koeppe RA; Frey KA; Kuhl DE; Kilbourn MR
J Cereb Blood Flow Metab; 1999 Dec; 19(12):1376-84. PubMed ID: 10598942
[TBL] [Abstract][Full Text] [Related]
32. In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine.
Kung HF; Lieberman BP; Zhuang ZP; Oya S; Kung MP; Choi SR; Poessl K; Blankemeyer E; Hou C; Skovronsky D; Kilbourn M
Nucl Med Biol; 2008 Nov; 35(8):825-37. PubMed ID: 19026944
[TBL] [Abstract][Full Text] [Related]
33. Sigma receptor binding of tetrabenazine series tracers targeting VMAT2 in rat pancreas.
Tsao HH; Skovronsky DM; Lin KJ; Yen TC; Wey SP; Kung MP
Nucl Med Biol; 2011 Oct; 38(7):1029-34. PubMed ID: 21982574
[TBL] [Abstract][Full Text] [Related]
34. PET Imaging of Vesicular Monoamine Transporter 2 in Early Diabetic Retinopathy Using [
Li J; Chen P; Bao Y; Sun Y; He J; Liu X
Mol Imaging Biol; 2020 Oct; 22(5):1161-1169. PubMed ID: 31650482
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain.
Kilbourn MR; Hockley B; Lee L; Hou C; Goswami R; Ponde DE; Kung MP; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):233-7. PubMed ID: 17383572
[TBL] [Abstract][Full Text] [Related]
36. Quantitative study of
Jung Lung H; Weng YH; Wen MC; Hsiao IT; Lin KJ
Sci Rep; 2018 Oct; 8(1):16027. PubMed ID: 30375444
[TBL] [Abstract][Full Text] [Related]
37. In vivo imaging of the brain vesicular monoamine transporter.
Vander Borght TM; Kilbourn MR; Koeppe RA; DaSilva JN; Carey JE; Kuhl DE; Frey KA
J Nucl Med; 1995 Dec; 36(12):2252-60. PubMed ID: 8523116
[TBL] [Abstract][Full Text] [Related]
38. In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [11C]methylphenidate and PET.
Fischer K; Sossi V; von Ameln-Mayerhofer A; Reischl G; Pichler BJ
Neuroimage; 2012 Feb; 59(3):2413-22. PubMed ID: 21945469
[TBL] [Abstract][Full Text] [Related]
39. Mapping the target localization and biodistribution of non-radiolabeled VMAT2 ligands in rat brain.
Deng A; Wu X; Zhou X; Zhang Y; Yin W; Qiao J; Zhu L
AAPS J; 2014 May; 16(3):592-9. PubMed ID: 24706374
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients.
Xu SS; Alexander PK; Lie Y; Dore V; Bozinovski S; Mulligan RS; Young K; Villemagne VL; Rowe CC
BMJ Open; 2018 Nov; 8(11):e025533. PubMed ID: 30446576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
